Life Medical Sciences (CHAI) for Hair Regrowth? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Life Medical Sciences (CHAI) for Hair Regrowth?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sean Lin who wrote ()	2/23/2000 8:11:00 PM
From: Art Odell	of 1152

Pivotal Trial planned for 3rd quarter LIFE MEDICAL SCIENCES ANNOUNCES SUCCESSFUL U.S. PILOT CLINICAL TRIAL RESULTS FOR REPEL-CV EDISON, NJ (February 24, 2000) . . . Life Medical Sciences, Inc. (OTCBB:CHAI) today announced successful results from its U.S. pilot human clinical trial of REPEL-CV?, a bioresorbable adhesion barrier film for the prevention/reduction of post-operative adhesions (scar tissue) in cardiovascular surgical procedures. The multi-center trial was designed to test the safety and biocompatibility of REPEL-CV when applied to the surface of the heart following open heart surgery. REPEL-CV was rated safe and well tolerated when compared to the control of standard surgical technique. Post-operative adhesions represent a pervasive and significant complication in the estimated one million open heart procedures performed annually worldwide. The global market for REPEL-CV is estimated to be approximately $250 million annually. The Company plans to initiate the U.S. pivotal clinical trial to determine the efficacy of REPEL-CV in the third quarter of this year. The initiation of the pivotal trial is contingent upon FDA approval of the trial protocol and the Company obtaining additional financing to fund the trial. Company Chairman, President & CEO Robert P. Hickey stated, "The cardiovascular surgery market represents a significant opportunity for Life Medical Sciences because of the clinical concerns expressed by surgeons about the presence of post-operative adhesions as well as the absence of any viable products to address this issue. Adhesions form between the surface of the heart and the sternum after virtually all open heart surgical procedures and have serious clinical and economic implications during secondary procedures (re-do?s) which account for approximately 15% of the cardiovascular procedures performed in the U.S." Hickey continued, "Our focus now is to complete arrangements for additional financing so that we can proceed aggressively into the pivotal clinical trial phase as a basis for gaining regulatory approval to market this important product." Life Medical Sciences Vice President and Chief Scientific Officer Dr. Eli Pines said, "We have recruited prominent cardiovascular surgeons to participate in the pivotal trial and, based on their input, have agreed upon a surgical protocol to assess the efficacy and the safety of REPEL-CV." Life Medical Sciences, Inc. is a biomaterials company engaged in the development and commercialization of innovative and cost-effective medical devices. The Company markets the CLINICEL© line of scar treatment products and is developing a broad range of bioresorbable polymer products to prevent/reduce post-operative adhesion formation.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next